Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Short Interest Up 95.8% in February

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 641,700 shares, an increase of 95.8% from the January 31st total of 327,700 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days.

Hansa Biopharma AB (publ) Stock Performance

OTCMKTS:HNSBF remained flat at $3.00 during midday trading on Friday. Hansa Biopharma AB has a one year low of $2.83 and a one year high of $3.65. The business’s 50 day simple moving average is $2.98 and its two-hundred day simple moving average is $3.09.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test.